Streetbeat News

Regulatory

PBTS

Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS) has regained compliance with the Nasdaq minimum bid price requirement. The company's ordinary shares have been at $1.00 per share or greater for 10 consecutive trading days, from September 22 to October 5, 2023. Previously, the company was not in compliance with the minimum bid price requirement for 30 consecutive business days from June 28, 2023 to August 10, 2023.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:41 pm

INZY

Inozyme Pharma, Inc. (NASDAQ:INZY) has highlighted the inclusion of Generalized Arterial Calcification of Infancy (GACI) in the Genomics England's Generation Study. This research initiative, developed to advance early detection and treatment of rare genetic conditions, is set to begin in late 2023. Inozyme is developing INZ-701, an enzyme replacement therapy, for the treatment of rare disorders like GACI.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:35 pm

JPM

JPMorgan Chase & Co. (NYSE:JPM) is set to release its Q3 earnings on Oct. 13, 2023, with analysts expecting a rise in earnings per share and revenue from the previous year. The bank is also reportedly accelerating the securitization of its loan portfolio in anticipation of new U.S. capital requirements. The article discusses how investors can earn a regular monthly income from JPMorgan's dividends, which currently yield 2.90% annually.

Portfolio Pulse from Priya Nigam

October 10, 2023 | 12:28 pm

SPY

USO

The Saudi Cabinet, following the OPEC+ Joint Ministerial Monitoring Committee (JMMC), has expressed its support for efforts to stabilize oil markets, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:26 pm

ATHX

Trading of Athersys shares has been temporarily halted due to pending news.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:25 pm

SRAD

Sportradar (NASDAQ:SRAD) has been selected as the official technology and services solution provider by the Taiwan Sports Lottery. The company will provide its end-to-end sportsbook and player account management solution, ORAKO, across more than 2,600 retail outlets in Taiwan and across web and mobile channels. The agreement will run from 2024 through 2033 and includes the delivery of the required equipment at retail stores. Sportradar has also established a local team in Taipei to provide operational support.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:14 pm

BTCUSD

ETHUSD

SPY

TSLA

U

The article covers a range of topics including tech stocks, crypto, US and world politics, Israel-Hamas conflict, tech, electric vehicles, consumer, communication, and space. Key points include Shiba Inu's burn rate doubling, Taiwan's call for peaceful coexistence with China, and various stock and crypto movements. Notable mentions include Unity Software, Tigo Energy, Ethereum, Tether Gold, Google, Apple, Oracle, Amazon, SpaceX, Tesla, Honda, Microsoft, and X.

Portfolio Pulse from Akanksha Bakshi

October 10, 2023 | 12:13 pm

CATX

Perspective Therapeutics (NYSE:CATX) announced two upcoming investigator-initiated trials (IIT) presented at the North American Neuroendocrine Tumor Society 2023 Symposium. The trials are Phase 1 and Phase 1/2 trials of Pb-212-VMT-alpha-NET in patients with metastatic or inoperable somatostatin receptors positive tumors and GI neuroendocrine tumors respectively. Enrollment for both studies is expected to commence in Q1 2024.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:07 pm

ACCD

AON

LLY

NVO

A survey by Accolade Inc and Savanta indicates that US employers are increasingly willing to include obesity medications like Novo Nordisk's Wegovy in their health coverage plans. The survey found that 43% of employers could potentially cover these drugs in 2024, up from the current 25%. Eli Lilly's Mounjaro, another GLP-1 diabetes drug, is also expected to gain approval for weight loss applications in the US this year. Aon Plc highlighted the economic implications of this trend, attributing a one percentage point rise in the anticipated 8.5% increase in employer healthcare costs to the uptick in employee utilization of weight-loss drugs.

Portfolio Pulse from Vandana Singh

October 10, 2023 | 12:06 pm

IMAB

I-Mab and ABL Bio have announced updates on their ongoing Phase 1 study of bispecific antibody TJ-L14B/ABL503. Among 14 efficacy-evaluable patients, one achieved a complete response, one had a partial response and two unconfirmed partial responses. The maximum tolerated dose has not yet been reached. Patent rights for TJ-L14B/ABL503 have been secured in Eurasia until 2039.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:06 pm